Rosiglitazone improved glycemic control and insulin-related indices, including lower HOMA(IR), higher QUICKI, and higher HOMA(beta-cell function).

From Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. · Confidence 0.98